CoChat
Sign Up
Cited by 388COVID-19 Clinical Research StudiesRespiratory Support and MechanismsSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.

Open access
Veiga, Viviane C, Prats, João A G G, Farias, Danielle L C, Rosa, Regis G, Dourado, Leticia K, Zampieri, Fernando G, Machado, Flávia R, Lopes, Renato D, Berwanger, Otavio, Azevedo, Luciano C P, Avezum, Álvaro, Lisboa, Thiago C, Rojas, Salomón S O, Coelho, Juliana C, Leite, Rodrigo T, Carvalho, Júlio C, Andrade, Luis E C, Sandes, Alex F, Pintão, Maria C T, Castro, Claudio G, Santos, Sueli V, de Almeida, Thiago M L, Costa, André N, Gebara, Otávio C E, de Freitas, Flávio G Rezende, Pacheco, Eduardo S, Machado, David J B, Martin, Josiane, Conceição, Fábio G, Siqueira, Suellen R R, Damiani, Lucas P, Ishihara, Luciana M, Schneider, Daniel, de Souza, Denise, Cavalcanti, Alexandre B, Scheinberg, Phillip·2021·BMJ
DOI 10.1136/bmj.n84PMC PMC7815251
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). Design: Randomised, open label trial. Setting: Nine hospitals in Brazil, 8 May to 17 July 2020. Participants: Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin). The data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group. Interventions: Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard care alone (n=64). Main outcome measure: The primary outcome, clinical status measured at 15 days using a seven level ordinal scale, was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met. Results: A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up. All patients in the tocilizumab group and two in the standard care group received tocilizumab. 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32). Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2). Adverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab. Conclusions: In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality. Trial registration: ClinicalTrials.gov NCT04403685 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.n84

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 40 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Veiga, V. C., Prats, J. A. G. G., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., Machado, F. R., Lopes, R. D., Berwanger, O., Azevedo, L. C. P., Avezum, Á., Lisboa, T. C., Rojas, S. S. O., Coelho, J. C., Leite, R. T., Carvalho, J. C., Andrade, L. E. C., Sandes, A. F., Pintão, M. C. T., Castro, C. G., Santos, S. V., de Almeida, T. M. L., Costa, A. N., Gebara, O. C. E., de Freitas, F. G. R., Pacheco, E. S., Machado, D. J. B., Martin, J., Conceição, F. G., Siqueira, S. R. R., Damiani, L. P., Ishihara, L. M., Schneider, D., de Souza, D., Cavalcanti, A. B., & Scheinberg, P.
Affiliations
  • Brazilian Research in Intensive Care Network (BR)
  • Beneficência Portuguesa de São Paulo (BR)
  • Hospital Israelita Albert Einstein (BR)
  • Hospital Alemão Oswaldo Cruz (BR)
  • Fleury S.A. (Brazil) (BR)
  • Hospital Sírio-Libanês (BR)
  • Hospital Santa Paula (BR)
  • Hospital Sepaco (BR)
  • Estátikos (Brazil) (BR)
  • Hospital Moinhos de Vento (BR)
Corresponding author
Veiga, Viviane C
ORCID
Venue
BMJ
Publisher
BMJ
Published
2021-01-20
Volume
372
Pages
n84
ISSN
1756-1833 (ISSN-L)
DOI
10.1136/bmj.n84
PMC
PMC7815251
OpenAlex
W3121693389
Cited by
388
References
40
Citations by year
2026: 3 · 2025: 12 · 2024: 24 · 2023: 51 · 2022: 105 · 2021: 191
FWCI
29.35
Type
journal article
Language
en
Open access
Licence
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
tocilizumab, COVID-19 pandemic, severe COVID-19, critical COVID-19, IL-6 receptor inhibition, cytokine storm, mechanical ventilation, mortality, adverse events, early trial termination, D-dimer, ferritin, lactate dehydrogenase, C-reactive protein, serum biomarkers, treatment efficacy and safety, Brazil, SARS-CoV-2
MeSH terms
COVID-19, COVID-19 Drug Treatment, Adolescent, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Female, Follow-Up Studies, Hospitalization, Humans, Infusions, Intravenous, Male, Middle Aged, Respiration, Artificial, Severity of Illness Index, Critical Illness, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review